Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Sanj Patel Sells 220,170 Shares

Key Points

• CEO Sanj Patel sold 220,170 shares for about $20.5 million, reducing his direct stake by 22.01%; the sale was made under a pre-arranged Rule 10b5-1 trading plan.
• Kiniksa reported quarterly EPS of $0.56, beating the $0.37 analyst estimate, and revenue of $285.97 million, above the $260.66 million consensus.
• The stock rose 2.7% to $93.29 in Tuesday midday trading. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $100.57.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 220,170 shares of the business's stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $93.27, for a total value of $20,535,255.90. Following the completion of the transaction, the chief executive officer directly owned 780,037 shares of the company's stock, valued at approximately $72,754,050.99. This trade represents a 22.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.7%

KNSA traded up $2.49 during midday trading on Tuesday, hitting $93.29. 1,021,631 shares of the company traded hands, compared to its average volume of 897,528. The company's 50-day moving average is $79.67 and its 200 day moving average is $60.56. The firm has a market capitalization of $7.28 billion, a PE ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KNSA. Rubric Capital Management LP lifted its position in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company's stock valued at $180,562,000 after purchasing an additional 421,347 shares in the last quarter. Pictet Asset Management Holding SA increased its position in Kiniksa Pharmaceuticals International by 41.3% in the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company's stock worth $64,182,000 after buying an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company's stock worth $39,086,000 after buying an additional 128,417 shares in the last quarter. Spruce Street Capital LP raised its stake in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company's stock worth $36,645,000 after buying an additional 326,081 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company's stock worth $35,436,000 after buying an additional 506,576 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Analyst Ratings Changes

A number of research firms have commented on KNSA. Canaccord Genuity Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 12th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Wednesday, October 28th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. Finally, The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a "buy" rating in a report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $100.57.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.